{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:24:00Z","timestamp":1740165840504,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s13730-017-0253-6","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T17:57:19Z","timestamp":1488909439000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-5930","authenticated-orcid":false,"given":"Tamami","family":"Fujiki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"253_CR1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy of TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686\u201392.","journal-title":"Int J Hematol"},{"key":"253_CR2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2169\/internalmedicine.52.9482","volume":"52","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Kotani S, Matsumura Y, et al. Successful treatment of a patient with multicentric Castleman\u2019s disease who presented with thrombocytopenia, ascites, renal failure, and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52:1503\u20137.","journal-title":"Intern Med"},{"key":"253_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ccr3.284","volume":"3","author":"S Tatekawa","year":"2015","unstructured":"Tatekawa S, Umemura K, Fukuyama R, et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3:472\u20138.","journal-title":"Clin Case Rep"},{"key":"253_CR4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1620\/tjem.236.289","volume":"236","author":"Y Konishi","year":"2015","unstructured":"Konishi Y, Takahashi S, Nishi K, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine a: possible pathogenic contribution of interleukin-2. Tohoku J Exp Med. 2015;236:289\u201395.","journal-title":"Tohoku J Exp Med"},{"key":"253_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3960\/jslrt.53.87","volume":"53","author":"N Iwaki","year":"2013","unstructured":"Iwaki N, Sato Y, Takata K, et al. Atypical hyaline vascular-type Catleman\u2019s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53:87\u201393.","journal-title":"J Clin Exp Hematop"},{"key":"253_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2162-3619-4-3","volume":"4","author":"S Tadesco","year":"2015","unstructured":"Tadesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman\u2019s disease with TAFRO syndrome with a pathophysiology targeted therapy\u2014a case report. Exp Hematol Oncol. 2015;4:3.","journal-title":"Exp Hematol Oncol"},{"key":"253_CR7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12185-016-1978-2","volume":"103","author":"S Fujiwara","year":"2016","unstructured":"Fujiwara S, Mochinaga H, Nakata H, et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol. 2016;103:718\u201323.","journal-title":"Int J Hematol"},{"key":"253_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2169\/internalmedicine.55.4710","volume":"55","author":"Y Yamaga","year":"2016","unstructured":"Yamaga Y, Tokuyama K, Kato T, et al. Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome. Intern Med. 2016;55:185\u201390.","journal-title":"Intern Med"},{"key":"253_CR9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum D, Nabel C, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220\u20136.","journal-title":"Am J Hematol"},{"key":"253_CR10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/357692a0","volume":"357","author":"SJ O\u2019Keefe","year":"1992","unstructured":"O\u2019Keefe SJ, Tamura J, Kincaid RL, et al. FK-506- and CsA- sensitive activation of the interleukin-2 promotor by calcineurin. Nature. 1992;357:692\u20134.","journal-title":"Nature"},{"key":"253_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.33077","volume":"29","author":"MB Atkins","year":"2002","unstructured":"Atkins MB. Interleukin-2 clinical applications. Semin Oncol. 2002;29:12\u20137.","journal-title":"Semin Oncol"},{"key":"253_CR12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105\u201316.","journal-title":"J Clin Oncol"},{"key":"253_CR13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ndt\/gfr245","volume":"27","author":"D Xu","year":"2012","unstructured":"Xu D, Lv J, Dong Y, et al. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transpl. 2012;27:119\u201325.","journal-title":"Nephrol Dial Transpl"},{"key":"253_CR14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfq427","volume":"26","author":"K El Karoui","year":"2011","unstructured":"El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transpl. 2011;26:599\u2013609.","journal-title":"Nephrol Dial Transpl"},{"key":"253_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12185-007-0015-x","volume":"87","author":"Y Morita-Hoshi","year":"2008","unstructured":"Morita-Hoshi Y, Tohda S, Miura O, et al. An autopsy case of multicentric Castleman\u2019s disease associated with interstitial nephritis and secondary AA amyloidosis. Int J Hematol. 2008;87:69\u201374.","journal-title":"Int J Hematol"},{"key":"253_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2431-14-139","volume":"14","author":"I Kubokawa","year":"2014","unstructured":"Kubokawa I, Yachie A, Hirase S, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman\u2019s disease. BMC Pediatr. 2014;14:139.","journal-title":"BMC Pediatr"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-017-0253-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-017-0253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-017-0253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T02:45:15Z","timestamp":1495248315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-017-0253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s13730-017-0253-6","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2017,3,7]]}}}